Fractyl Health Inc
Research Fractyl Health Inc (GUTS) on Bullrun: market cap USD 58.30M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGUTS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 58.30M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 25.54M
- Free cash flow-USD 15.90M
Valuation Snapshot
latest market cap is USD 58.30M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 140.95M | -USD 90.89M | n/a | -1.86 | USD 81.54M | USD 61.65M | USD 9.46M |
| FY2024 | USD 93.00K | -USD 68.69M | -USD 67.29M | 46.2% | -1.62 | USD 67.46M | USD 62.50M | USD 28.42M |
| FY2023 | USD 120.00K | -USD 77.09M | -USD 43.18M | 35.8% | -45.29 | USD 33.21M | USD 86.39M | -USD 325.06M |
| FY2022 | USD 0 | -USD 46.45M | -USD 46.30M | n/a | -1.34 | USD 49.27M | USD 19.48M | -USD 252.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 58.30M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 337.42M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 100.44M | n/a | n/a | n/a |
About Fractyl Health Inc
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Fractyl Health Inc's market cap?
Fractyl Health Inc's market capitalization is USD 58.30M.
What does Fractyl Health Inc do?
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.